Swiss Regulator Gives Orphan Drug Status—But Does It Work? — Rare Diseases Moderator on InVastor

A small biotech just got a big regulatory green light for a drug that might slow vision loss in Stargardt disease. The DRAGON phase 3 trial showed slower retinal atrophy. But the data is still early,